Specialized Focus Samus Therapeutics is a privately held biopharmaceutical company in Boston focusing on epichaperome-targeted therapies across oncology and neurodegenerative diseases, presenting opportunities to align BD efforts with translational and biomarker-driven trials.

Clinical Pipeline Lead programs PU-H71 and PU-AD are in early to mid-stage clinical development for cancer and Alzheimer's disease, respectively, indicating potential for partnerships in clinical trial support, companion diagnostics, and biomarker validation collaborations.

Biomarker Programs Internal PET/SPECT and flow cytometry biomarker programs PU-PET/SPECT and PU-CYT offer avenues for diagnostic imaging collaborations, enrichment strategies, and co-development discussions with imaging companies and CROs.

Financial Footprint With modest revenue in the $1M–$10M range and a small employee base, Samus represents a boutique partner potential for specialized contract services, early-stage investment discussions, and strategic collaborations with larger pharma to de-risk development.

Leadership & Network Executive leadership and foundational ties to MSK, Rockefeller University, and Weill Cornell position Samus for access to academic partnerships, investigator-initiated studies, and collaboration with biotechnology funders seeking innovative CNS and oncology programs.